SARS-CoV-2-PLLAV vaccine

The SARS-CoV-2-PLLAV vaccine is a preclinical vaccine candidate developed by ViroVet in collaboration with the Rega Institute at KU Leuven. It utilizes the proprietary Plasmid-Launched Live Attenuated Virus (PLLAV) technology platform. This approach involves the delivery of a DNA plasmid that, once inside host cells, initiates the production of a live attenuated version of the SARS-CoV-2 virus. This attenuated virus replicates locally to stimulate a broad and robust immune response, including both humoral and cellular immunity, mimicking a natural infection without causing disease. Preclinical studies in hamster models have demonstrated that the vaccine candidate can induce high levels of neutralizing antibodies and provide protection against viral challenge.